SOURCE: Apricus Biosciences, Inc.

Apricus Biosciences, Inc.

April 20, 2015 11:30 ET

Apricus Biosciences, Inc. to Present at Taglich Brothers 12th Annual Investment Conference

NEW YORK, NY--(Marketwired - Apr 20, 2015) - Taglich Brothers, Inc. is pleased to announce that Apricus Biosciences, Inc. (NASDAQ: APRI) will be presenting at our 12th Annual Investment Conference May 5, 2015 in New York City. To view the webcast visit http://www.taglichbrothers.com/conference/conferencewebcast.php.

About Taglich Brothers

Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community. 

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus' lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus' marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus' second-generation room temperature Vitaros is under development. Apricus recently commenced a Phase 2a trial for RayVa, its product candidate for the treatment of the circulatory disorder Raynaud's phenomenon. Additionally, Apricus plans to initiate a Phase 2 trial for fispemifene, a selective estrogen receptor modulator for the treatment of male secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms. Apricus is currently seeking a strategic partner to fund development of Femprox®, a product candidate for the treatment of female sexual interest/arousal disorder that completed an approximately 400-subject proof-of-concept study. 

Contact Information